Navegando por Palavras-chave "Central obesity"

Agora exibindo 1 - 2 de 2
  • Imagem de Miniatura
    Item
    Acesso aberto (Open Access)
    Orlistat and cardiovascular risk profile in hypertensive patients with metabolic syndrome: the ARCOS study
    (Sociedade Brasileira de Endocrinologia e Metabologia, 2006-04-01) Zanella, Maria Teresa [UNIFESP]; Uehara, Marcelo Hiroshi [UNIFESP]; Ribeiro, Artur Beltrame [UNIFESP]; Bertolami, Marcelo; Falsetti, Ana Claudia; Yunes, Mirela A.; Universidade Federal de São Paulo (UNIFESP); Instituto Dante Pazzaneze de Cardiologia Service of Cardiology; Roche Laboratories
    Weight loss improves metabolic abnormalities and reduces cardiovascular risk in obese hypertensive patients. To evaluate the impact of a sustained weight loss on coronary risk, 181 hypertensive patients with metabolic syndrome underwent to orlistat therapy, 120 mg, t.i.d., plus diet for 36 weeks. During therapy, Framingham risk scores (FRS) were calculated for determination of coronary heart disease risk in ten years. Body mass index decreased from 35.0 ± 4.2 to 32.6 ± 4.5 kg/m² (p< 0.0001) and waist circumference from 108.1 ± 10.1 to 100.5 ± 11.1 cm (p< 0.0001), at the end of the study period (week 36). Systolic and diastolic blood pressure showed reductions after the two first weeks, which were maintained up to the end of the study. A clear shift to the left in FRS distribution curve occurred at the end of the study, compared to baseline, indicating a reduction in coronary risk. Over all patients at risk, 49.2% moved to a lower risk category. A weight loss > 5% occurred in 64.6% of all patients, associated with improvement in glucose metabolism. Among those with abnormal glucose metabolism, 38 out 53 patients (71.7%) improved their glucose tolerance (p< 0.0005). In conclusion, long-term orlistat therapy helps to reduce and maintain a lower body weight, decreasing risk of coronary disease and improving glucose metabolism, thus protecting against type 2 diabetes.
  • Nenhuma Miniatura disponível
    Item
    Somente Metadadados
    Prospective Evaluation of Waist Circumference and Visceral Adipose Tissue in Patients with Chronic Kidney Disease
    (Karger, 2010-01-01) Velludo, Claudia M. O. [UNIFESP]; Kamimura, Maria Ayako [UNIFESP]; Sanches, Fabiana M. R. [UNIFESP]; Lemos, Marcelo M. [UNIFESP]; Canziani, Maria Eugenia F. [UNIFESP]; Pupim, Lara B.; Draibe, Sergio A. [UNIFESP]; Cuppari, Lilian [UNIFESP]; Universidade Federal de São Paulo (UNIFESP); Vanderbilt Univ
    Background: Waist circumference (WC), a simple anthropometric measure, is associated with visceral adipose tissue (VAT) in cross-sectional studies, and thus has been used as a surrogate marker for VAT. However, associations between changes over time in WC and VAT have not been studied in chronic kidney disease (CKD) patients. Methods: This prospective study included 87 nondialysis-dependent CKD patients (54 males, 56.2 +/- 10.4 years, BMI 27.3 +/- 5.1, GFR 35.9 +/- 14.6 ml/min/1.73 m(2)). VAT area was measured by computed tomography (CT) and WC was measured at the umbilicus level at baseline and after 12 months. Results: Changes in WC correlated significantly but weakly with changes in VAT (r = 0.26, p = 0.016), likely due to a substantially smaller change in WC compared to changes in VAT. This was also reflected by a kappa coefficient of 0.26, i.e. indicative of poor agreement between WC and CT measurements in regards to quantification of changes in VAT. Likewise, the receiver operating characteristic curve analysis identified WC as poor predictor of changes in VAT (area under the curve = 0.62). Conclusion: Anthropometric measurement of WC is poorly correlated with changes in VAT measured by CT in nondialysis-dependent CKD patients. Therefore, caution should be taken when using WC as a surrogate marker of VAT changes in this population. Copyright (C) 2009 S. Karger AG, Basel